Company intelligence / Profile preview
ProtoKinetix
Dalton, Ohio, United Statesprotokinetix.com ↗
- Ownership
- Public · PKTX
- Employees
- ~5
- Development stage
- Phase 1
01
Overview
ProtoKinetix has developed a patented molecule called AAGP®, an anti-aging glycopeptide with demonstrated abilities to protect cells from inflammation and extreme conditions. The company’s research suggests potential transformative applications in ophthalmology, dermatology, organ transplantation, and biomanufacturing. Clinical results are primarily pre-clinical or early-stage; there are no reported late-phase clinical trial outcomes as of May 2025.[1][3][4]
- Therapeutic areas
- ImmunologyOtherDermatologyOphthalmology
- Modalities
- Glycopeptides (specifically anti-aging glycopeptides/AAGP®)anti-freeze glycoproteins (AFGPs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Financials
- Market cap
- $123.5K
- Total revenue
- $0
- Enterprise value
- $123K
Beyond the preview
Go deeper on ProtoKinetix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProtoKinetix.